Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Rating) major shareholder South Cone Investments Limited purchased 3,510 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The shares were acquired at an average cost of $5.49 per share, for a total transaction of $19,269.90. Following the purchase, the insider now owns 6,790,127 shares of the company’s stock, valued at $37,277,797.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
South Cone Investments Limited also recently made the following trade(s):
- On Monday, March 20th, South Cone Investments Limited purchased 532 shares of Rani Therapeutics stock. The shares were acquired at an average cost of $6.29 per share, with a total value of $3,346.28.
- On Thursday, March 16th, South Cone Investments Limited acquired 1,325 shares of Rani Therapeutics stock. The stock was acquired at an average cost of $6.07 per share, with a total value of $8,042.75.
- On Monday, March 13th, South Cone Investments Limited bought 2,463 shares of Rani Therapeutics stock. The stock was purchased at an average price of $6.14 per share, with a total value of $15,122.82.
- On Wednesday, March 8th, South Cone Investments Limited acquired 1,702 shares of Rani Therapeutics stock. The stock was purchased at an average cost of $6.58 per share, for a total transaction of $11,199.16.
- On Monday, March 6th, South Cone Investments Limited bought 1,100 shares of Rani Therapeutics stock. The stock was bought at an average price of $6.39 per share, for a total transaction of $7,029.00.
- On Thursday, March 2nd, South Cone Investments Limited purchased 3,900 shares of Rani Therapeutics stock. The stock was bought at an average cost of $6.31 per share, for a total transaction of $24,609.00.
- On Monday, February 27th, South Cone Investments Limited purchased 3,541 shares of Rani Therapeutics stock. The stock was bought at an average cost of $6.30 per share, for a total transaction of $22,308.30.
- On Friday, February 24th, South Cone Investments Limited acquired 5,451 shares of Rani Therapeutics stock. The shares were acquired at an average cost of $6.09 per share, with a total value of $33,196.59.
- On Tuesday, February 21st, South Cone Investments Limited bought 3,080 shares of Rani Therapeutics stock. The shares were purchased at an average cost of $5.94 per share, for a total transaction of $18,295.20.
- On Thursday, February 16th, South Cone Investments Limited bought 9,500 shares of Rani Therapeutics stock. The shares were bought at an average cost of $5.49 per share, with a total value of $52,155.00.
Rani Therapeutics Price Performance
Shares of NASDAQ RANI opened at $5.16 on Friday. The business has a 50-day moving average price of $5.94 and a 200 day moving average price of $6.93. The company has a debt-to-equity ratio of 0.39, a current ratio of 20.96 and a quick ratio of 20.96. Rani Therapeutics Holdings, Inc. has a 52-week low of $3.65 and a 52-week high of $14.90.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Rani Therapeutics in a research note on Thursday, March 23rd.
Institutional Trading of Rani Therapeutics
A number of institutional investors have recently bought and sold shares of RANI. BlackRock Inc. boosted its stake in shares of Rani Therapeutics by 37.7% during the first quarter. BlackRock Inc. now owns 157,374 shares of the company’s stock valued at $2,125,000 after acquiring an additional 43,076 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Rani Therapeutics by 1.6% in the first quarter. Vanguard Group Inc. now owns 290,107 shares of the company’s stock valued at $3,916,000 after acquiring an additional 4,561 shares during the last quarter. State Street Corp boosted its holdings in Rani Therapeutics by 32.7% in the first quarter. State Street Corp now owns 26,142 shares of the company’s stock valued at $353,000 after acquiring an additional 6,442 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Rani Therapeutics in the 1st quarter valued at $362,000. Finally, Millennium Management LLC increased its holdings in Rani Therapeutics by 243.7% in the 2nd quarter. Millennium Management LLC now owns 111,781 shares of the company’s stock valued at $1,155,000 after purchasing an additional 79,256 shares in the last quarter. 6.43% of the stock is currently owned by hedge funds and other institutional investors.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on Rani Therapeutics (RANI)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
